Precision BioSciences Inc., a clinical-stage gene editing company based in Durham, North Carolina, has announced its focus on the development of ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases. The company's ARCUS platform, which is used to cure genetic disorders, is at the forefront of the company's efforts. Precision BioSciences Inc. has also unveiled its ex vivo allogeneic CAR T Immunotherapy, which utilizes cells that have been genetically engineered to detect and kill cancer cells. The company's portfolio also includes PBCAR0191 and PBCAR19B, anti-cancer therapeutics for treating acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia, respectively. Precision BioSciences Inc.'s investigations of CAR T cell candidate PBCAR269A show promise in the treatment of B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma-secretase inhibitor. The company has ongoing development and commercial licenses with Les Laboratoires Servier, Tiziana Life Sciences, iECURE Inc., and Novartis Pharma AG.
Precision BioSciences, Inc.'s ticker is DTIL
The company's shares trade on the NASDAQ stock exchange
They are based in Durham, North Carolina
There are 201-500 employees working at Precision BioSciences, Inc.
It is https://precisionbiosciences.com/
Precision BioSciences, Inc. is in the Healthcare sector
Precision BioSciences, Inc. is in the Biotechnology industry
The following five companies are Precision BioSciences, Inc.'s industry peers: